A Tumor-Agnostic NTRK (TRK) Inhibitor.
Cell
; 177(1): 8, 2019 03 21.
Article
in En
| MEDLINE
| ID: mdl-30901551
ABSTRACT
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Full text:
1
Database:
MEDLINE
Main subject:
Pyrazoles
/
Pyrimidines
/
Receptor Tyrosine Kinase-like Orphan Receptors
Limits:
Humans
Language:
En
Journal:
Cell
Year:
2019
Type:
Article